Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia

Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data

(2015) Giacomo Novara et al.   BJU INTERNATIONAL

Silodosin to Facilitate Passage of Ureteral Stones: A Multi-institutional, Randomized, Double-blinded, Placebo-controlled Trial

(2015) Roger L. Sur et al.   EUROPEAN UROLOGY

Intraoperative floppy iris syndrome associated with silodosin

(2014) Tumay Ipekci et al.   ACTA OPHTHALMOLOGICA

775 The “Silodosin in Real-life Evaluation (SiRE)” study: A European phase IV clinical study with silodosin in the treatment of LUTS/BPH

(2014) C.R. Chapple   EUROPEAN UROLOGY SUPPLEMENTS

Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms

(2014) Matthias Oelke et al.   Expert Opinion On Drug Safety

Latest pharmacotherapy options for benign prostatic hyperplasia

(2014) Andrea Russo et al.   EXPERT OPINION ON PHARMACOTHERAPY

Reasons for Prescription Change of α1-Blockers in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

(2014) Tae Nam Kim et al.   UROLOGY

Safety and Efficacy of 8-mg Once-daily vs 4-mg Twice-daily Silodosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (SILVER Study): A 12-Week, Double-blind, Randomized, Parallel, Multicenter Study

(2014) Myung-Soo Choo et al.   UROLOGY

Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies

(2014) Andreas Eisenhardt et al.   WORLD JOURNAL OF UROLOGY

Current medical treatment of lower urinary tract symptoms/BPH

(2013) João Silva et al.   CURRENT OPINION IN UROLOGY

EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction

(2013) Matthias Oelke et al.   EUROPEAN UROLOGY

Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates

(2013) U. Capitanio et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial

(2013) Kenya Yamaguchi et al.   INTERNATIONAL JOURNAL OF UROLOGY

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

(2013) T Watanabe et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Prospective Randomized Placebo-controlled Study to Assess the Safety and Efficacy of Silodosin in the Management of Acute Urinary Retention

(2013) Santosh Kumar et al.   UROLOGY

Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology

(2013) S. T. Bird et al.   BMJ-British Medical Journal

The Influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Silodosin in Healthy Chinese Volunteers

(2012) Zining Wang et al.   Drug Metabolism and Pharmacokinetics

755 Effects of the long-term treatment with silodosin in men with LUTS suggestive of BPH. A 9-month, open-label extension study

(2012) T. Tammela et al.   EUROPEAN UROLOGY SUPPLEMENTS

New clinical evidence of silodosin, an α1A selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms

(2012) Masaki Yoshida et al.   INTERNATIONAL JOURNAL OF UROLOGY

Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized multicenter study

(2012) Toshiro Shirakawa et al.   INTERNATIONAL JOURNAL OF UROLOGY

Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

(2012) Giacomo Novara et al.   WORLD JOURNAL OF UROLOGY

Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

(2011) Hong-Jeng Yu et al.   BJU INTERNATIONAL

α-Blockers for benign prostatic hyperplasia

(2011) Herbert Lepor et al.   CURRENT OPINION IN UROLOGY

Silodosin

(2011) Monique P. Curran   DRUGS

Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy

(2011) Andrea Russo et al.   EUROPEAN UROLOGY SUPPLEMENTS

Comparison of Prophylactic Naftopidil, Tamsulosin, and Silodosin for 125I Brachytherapy–Induced Lower Urinary Tract Symptoms in Patients With Prostate Cancer: Randomized Controlled Trial

(2011) Hideyasu Tsumura et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled Study

(2011) J. Curtis Nickel et al.   JOURNAL OF UROLOGY

Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia

(2011) Kevin T. McVary et al.   JOURNAL OF UROLOGY

Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled Study

(2010) J Morganroth et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Widespread Population Study of Actual Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Across Europe and Beyond Official Clinical Guidelines

(2010) Jean-Nicolas Cornu et al.   EUROPEAN UROLOGY

Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe

(2010) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Profile of Silodosin

(2010) Francesco Montorsi   EUROPEAN UROLOGY SUPPLEMENTS

The Pharmacological Profile of the α1A-Adrenoceptor Antagonist Silodosin

(2010) Martin C. Michel   EUROPEAN UROLOGY SUPPLEMENTS

Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability

(2010) Herbert Lepor et al.   PHARMACOTHERAPY

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH

(2010) C G Roehrborn et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Ejaculation Disorder Is Associated With Increased Efficacy of Silodosin for Benign Prostatic Hyperplasia

(2010) Yukio Homma et al.   UROLOGY

Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective α1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men

(2010) Scott A. MacDiarmid et al.   UROLOGY

Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies

(2009) Leonard S. Marks et al.   JOURNAL OF UROLOGY

Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study

(2009) Yoshihisa Matsukawa et al.   JOURNAL OF UROLOGY

Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month, Open-label Extension Study

(2009) Leonard S. Marks et al.   UROLOGY